Wall Street analysts expect the company to report fourth quarter earnings of $0.69 per share, down from $0.80 in the same quarter last year.
The company named industry veteran Tim Wentworth as chief executive late Tuesday, and he will take over as the global pharmacy chain is in a tough spot.
Shares are down 40.1% this year, despite an extremely high dividend yield of 8.4%, according to FactSet, which some analysts have suggested is unsustainable.Wentworth, most recently CEO of a Cigna division that includes its pharmacy benefit manager, was formerly the CEO of Express Scripts, the pharmacy benefit manager that Cigna acquired in 2018.
Wall Street analysts expect the company to report fourth quarter earnings of $0.69 per share, down from $0.80 in the same quarter last year, according to FactSet. They expect full-year fiscal 2023 earnings of $4, down from $5.04 in 2022 and $4.91 in 2021. Analysts expect sales of $34.8 billion for the quarter.
In a note on Tuesday, shortly ahead of the CEO announcement, Mizuho analyst Ann Hynes, who has a neutral rating on Walgreens, dropped her target price to $25, from $31. J.P. Morgan analyst Lisa Gill, who also has a neutral rating on the stock, cut her target price to $27, from $33, on Oct. 5.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Colorado Walgreens customers face prescription delays amid reports of national walkoutsJaclyn Allen is a Denver7 Weekend Anchor and Contact7 Reporter.
Read more »
Southland crime: Armed robberies in Evergreen Park, shooting in Park Forest, and moreCrime reports from south suburban agencies from police and court reports and news releases.
Read more »
Voxx International, Walgreens rise; Exxon Mobil, DaVita fall, Wednesday, 10/11/2023Stocks that are trading heavily or have substantial price changes on Wednesday:
Read more »
Walgreens Boots Alliance Names Tim Wentworth CEOHe succeeds Roz Brewer, who revealed her departure last month.
Read more »
Jim Cramer praises Walgreens new CEO pick, says buy the stock 'perhaps aggressively'Tim Wentworth is the right choice to lead Walgreens (WBA) in its transition to offering more health-care services, CNBC's Jim Cramer said Wednesday.
Read more »
Jim Cramer praises Walgreens new CEO pick, says buy the stock ‘perhaps aggressively'Tim Wentworth is the right choice to lead Walgreens (WBA) in its transition to offering more health-care services, CNBC’s Jim Cramer said Wednesday.
Read more »